Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label study of tocilizumab in rheumatoid arthritis with inadequate response to DMARDs and/or anti-TNF therapy
2008-000587-17Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoints: Incidence of adverse events and Incidence of serious adverse events. Started Apr 2008; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-000587-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000587-17.